Anson Funds Management LP Increases Stake in Pfizer Inc. (NYSE:PFE)

Anson Funds Management LP raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 20.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 120,000 shares of the biopharmaceutical company's stock after buying an additional 20,000 shares during the period. Anson Funds Management LP's holdings in Pfizer were worth $3,184,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the fourth quarter worth approximately $31,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company's stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.19 on Friday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a market cap of $137.19 billion, a PE ratio of 17.16, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a fifty day moving average price of $24.34 and a 200 day moving average price of $25.78.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the prior year, the company posted $0.82 earnings per share. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.11%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is 124.64%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on PFE shares. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.